Clinical Trial Update: Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating thalidomide with peginterferon and ribavirin in interferon-resistant hepatitis C. The current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)
• Thalidomide (thalidomide)

Snippet

Sponsor: Valme University Hospital | Conditions: Hepatitis C | Phase 2 | Status: UNKNOWN